Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
buspirone + alprazolam
- Development stage
- Unknown
- Lead developer
- Bristol Myers Squibb
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
A combination of two anxiolytic medications with different mechanisms of action. Buspirone is a non-benzodiazepine anxiolytic that acts primarily as a serotonin 5-HT1A receptor agonist, while alprazolam is a benzodiazepine that enhances the effect of GABA in the brain. This combination is sometimes used during alprazolam tapering to manage anxiety symptoms while reducing benzodiazepine dependence.
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))GABRR (GABA-A receptor subunit rho)GABA-B (Gamma-aminobutyric acid receptor type B)
Beyond the preview
Go deeper on buspirone + alprazolam.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on buspirone + alprazolam.